MT1X (Metallothionein 1X)

Our study establishes MRGs, particularly the core genes MT1M and MT1X, as crucial players in BC heterogeneity and pathogenesis. They serve as promising diagnostic biomarkers and potential therapeutic targets, with their tumor-suppressive roles likely mediated through the modulation of key oncogenic signaling pathways.

LINC00641 is highly expressed in AML, and inhibition of LINC00641 expression can inhibit cell proliferation, migration, and invasion and increase apoptosis by regulating the miR-204-5p/MT1X axis.

It was found that MT1X knockdown significantly upregulated H2O2-induced intracellular ROS, activated the EMT pathway, and ultimately promoted cell migration and invasion whereas Trolox inhibited cell migration and invasion by suppressing the elevated ROS induced by MT1X knockdown. Here, we reported that MT1X is low-expressed in RCC and that MT1X knockdown promotes cell migration and invasion through the upregulation of intracellular ROS levels, thereby activating the EMT pathway.

We further explore this feature of ZnO nanoparticles for the delivery of chemotherapeutics to mouse and rabbit cancer models. Our findings demonstrate that ZnO nanoparticles derived from supplements can serve as a multifunctional drug delivery and cancer immunotherapy platform.

The M2d-mtCAF axis may play an important role in GC angiogenesis. This study not only enhances our understanding of the TME heterogeneity in GC but also sheds light on the interaction between CAFs and tumor-associated macrophages (TAMs) in tumor angiogenesis.

Knockdown of MT1X significantly promoted the growth rate of oesophageal cancer cells. Based on the single cell sequencing technology and transcriptomic analysis, we confirmed that there is a close association between the lysosomal pathway and the immune infiltration and treatment sensitivity of ESCC, which may be a potential target for a new direction of ESCC therapy.

Further in vivo antitumor activity was well reported in SCID female mice. Overall, this study suggests that the CNB-PLGA-PSar-NPs are a promising drug delivery system for the treatment of HCC, and further research is needed to investigate their potential in clinical treatment.

Laboratory experiments confirmed bioinformatic findings. MT1X was also found to be an independent prognostic biomarker for ccRCC and is involved in immune system regulation.

In vitro cell function experiments verified that silencing MT1X inhibited the proliferation of AML cells, sensitized cells to doxorubicin, and increased their apoptosis...The rescue experiments further confirmed that miR-376a-3p could reverse the promotion of MT1X overexpression on the progress of AML cells. Taken together, our results revealed that elevated MT1X expression might be involved in the mechanism underlying AML progression, indicating that the miR-376a/MT1X axis might serve as a promising novel target for the effective treatment of patients with AML.